Johnson & Johnson (JNJ)
158.51
+0.33
(+0.21%)
USD |
NYSE |
Jun 07, 16:00
158.60
+0.09
(+0.06%)
After-Hours: 20:00
Johnson & Johnson Enterprise Value: 439.36B for June 6, 2023
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 06, 2023 | 439.36B |
| June 05, 2023 | 439.73B |
| June 02, 2023 | 436.22B |
| June 01, 2023 | 429.90B |
| May 31, 2023 | 431.25B |
| May 30, 2023 | 429.46B |
| May 26, 2023 | 429.41B |
| May 25, 2023 | 429.56B |
| May 24, 2023 | 435.41B |
| May 23, 2023 | 435.80B |
| May 22, 2023 | 435.96B |
| May 19, 2023 | 441.26B |
| May 18, 2023 | 440.14B |
| May 17, 2023 | 441.47B |
| May 16, 2023 | 442.38B |
| May 15, 2023 | 442.92B |
| May 12, 2023 | 446.12B |
| May 11, 2023 | 446.66B |
| May 10, 2023 | 448.38B |
| May 09, 2023 | 446.82B |
| May 08, 2023 | 450.09B |
| May 05, 2023 | 451.06B |
| May 04, 2023 | 449.63B |
| May 03, 2023 | 451.55B |
| May 02, 2023 | 457.16B |
| Date | Value |
|---|---|
| May 01, 2023 | 453.45B |
| April 28, 2023 | 453.71B |
| April 27, 2023 | 451.89B |
| April 26, 2023 | 450.90B |
| April 25, 2023 | 457.55B |
| April 24, 2023 | 453.65B |
| April 21, 2023 | 451.08B |
| April 20, 2023 | 453.33B |
| April 19, 2023 | 450.60B |
| April 18, 2023 | 446.65B |
| April 17, 2023 | 458.76B |
| April 14, 2023 | 459.20B |
| April 13, 2023 | 459.90B |
| April 12, 2023 | 454.21B |
| April 11, 2023 | 455.12B |
| April 10, 2023 | 455.25B |
| April 06, 2023 | 457.41B |
| April 05, 2023 | 458.60B |
| April 04, 2023 | 440.10B |
| April 03, 2023 | 435.84B |
| March 31, 2023 | 433.40B |
| March 30, 2023 | 417.14B |
| March 29, 2023 | 416.83B |
| March 28, 2023 | 412.94B |
| March 27, 2023 | 416.80B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
301.41B
Minimum
Mar 23 2020
492.23B
Maximum
Apr 25 2022
412.50B
Average
410.22B
Median
Enterprise Value Benchmarks
| Amgen Inc | 148.24B |
| Gilead Sciences Inc | 114.36B |
| Eli Lilly and Co | 435.91B |
| Merck & Co Inc | 299.57B |
| Moderna Inc | 39.45B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -68.00M |
| Revenue (Quarterly) | 24.75B |
| Total Expenses (Quarterly) | 17.74B |
| EPS Diluted (Quarterly) | -0.03 |
| Gross Profit Margin (Quarterly) | 66.08% |
| Profit Margin (Quarterly) | -0.27% |
| Earnings Yield | 3.02% |
| Operating Earnings Yield | 5.79% |
| Normalized Earnings Yield | 3.933 |